Nyxoah S.A. (NASDAQ:NYXH) Short Interest Update

Nyxoah S.A. (NASDAQ:NYXH) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decrease of 17.4% from the October 15th total of 71,200 shares. Based on an average daily volume of 63,200 shares, the short-interest ratio is currently 0.9 days. Currently, 0.4% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Oppenheimer reduced their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a research note on Tuesday, November 5th. Finally, HC Wainwright lowered their target price on Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nyxoah presently has an average rating of “Buy” and a consensus price target of $17.00.

Nyxoah Trading Down 2.5 %

NYXH opened at $8.22 on Friday. The stock has a 50-day moving average of $9.06 and a 200 day moving average of $8.72. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00.

Hedge Funds Weigh In On Nyxoah

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Kovack Advisors Inc. purchased a new stake in Nyxoah during the 3rd quarter valued at $96,000. Ikarian Capital LLC purchased a new stake in shares of Nyxoah in the first quarter valued at $684,000. CVI Holdings LLC purchased a new stake in shares of Nyxoah in the second quarter valued at $1,292,000. Finally, Iron Triangle Partners LP bought a new stake in shares of Nyxoah in the 1st quarter worth about $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.